Docoh
Loading...

44 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q3
PCSA Processa Pharmaceuticals Inc
11 Nov 21
Quarterly report
7:00pm
30, 2021, we experienced increases in payroll and related costs of $390,220 from increased employee salary rates, hiring additional personnel … , timing, and costs of seeking regulatory approvals; the costs associated with hiring additional personnel and consultants as our pre-clinical
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
from their hiring date. We valued the restricted stock awards based on the closing shares price on the date of grant. At March 31, 2021, we had
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
in hiring, promotion or pay of employees, nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous foreign laws
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
experienced increases in payroll and related costs of $339,142 from raised employee salary rates, hiring additional personnel and stock-based compensation … ; the outcome, timing, and costs of seeking regulatory approvals; the costs associated with hiring additional personnel and consultants as our pre-clinical
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
restricted stock awards to our Chief Operating Officer upon hire which vest one year from their hiring date. We valued the restricted stock awards based
8-K
EX-10.1
lrc29wt cao9c
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
10-Q
oc010v5b w47o37ezy
13 May 21
Quarterly report
4:30pm
10-K
l0k0xm75gf w3vy6
24 Mar 21
Annual report
8:00pm
8-K
EX-1.1
j6bqjuh1irhjbp54q
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
cw0hghg4d 3t2yoyi9q
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
hjetgtk
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
ndok7h
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
pqkd2jmmxb cgu1c
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.13
a4v8ippdut5bfytiml7w
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.11
sgxu8b
16 Sep 20
IPO registration (amended)
8:00pm
8-K
EX-10.1
jtn18fl
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
p4criuh su5
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
S-1/A
71j2f8d4kj qko3ib
17 Jul 20
IPO registration (amended)
5:25pm
10-K
ppivlg8n
5 Mar 20
Annual report
7:00pm
S-1
3d4a1qu16u839 pu03i
13 Dec 19
IPO registration
5:32pm